EVGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Evogene Ltd (EVGN) is not a good buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock lacks strong positive catalysts, shows weak financial performance, and has no significant trading signals or recent news to support a bullish outlook.
The MACD is positive and expanding, indicating a mild bullish trend. RSI is neutral at 57.521, and moving averages are converging, suggesting no clear directional trend. Key support and resistance levels are Pivot: 0.813, R1: 0.88, and S1: 0.746. Overall, the technical indicators do not strongly favor a buy.
Gross margin increased by 25.88% YoY to 66.88%. Analysts maintain a Buy rating with a reduced price target of $1.75, citing the company's focus on its ChemPass AI discovery engine and collaborations.
Net income plummeted by 1343.33% YoY, and EPS fell by 1116.67% YoY. No recent news or significant trading activity from hedge funds, insiders, or Congress. Lack of strong trading signals from AI Stock Picker or SwingMax.
In Q4 2025, revenue dropped significantly to $314,000 (-80.51% YoY). Net income fell to -$5,309,000 (-1343.33% YoY), and EPS dropped to -0.61 (-1116.67% YoY). Despite these declines, gross margin improved to 66.88% (+25.88% YoY).
Alliance Global lowered the price target from $2.50 to $1.75 but maintained a Buy rating. Analysts highlight the company's focus on its ChemPass AI discovery engine and ongoing collaborations, with molecules expected to enter preclinical testing by 1H27.
